Why is there a clause in the GLD prospectus that states GLD has no right to audit subcustodial gold holdings? Why would the organizations behind GLD forfeit this right and create this massive audit loophole? I haven't heard of a single good reason for the existence of this loophole so far. In addition to the audit loophole, GLD claims to be fully backed by physical gold bullion but yet it refuses to give retail investors the right to redeem for any of these ‘claimed’ gold bullion. There are other issues as well that I welcome everyone to verify for themselves:
"CNBC's Bob Pisani also made a highly publicized visit to GLD's gold vault in a segment called Gold Rush: The Mother Lode. GLD's administration organized this visit to show that GLD's gold actually exists. However, the gold bar held up by Mr. Pisani showed a serial number of ZJ6752 which did not show up on the latest bar list during that time. It was later found that this "GLD" bar actually belonged to ETF Securities..."
"Did anyone try calling the GLD hotline at 866 320 4053 in search of numerical details on GLD's insurance? The prospectus vaguely states "The Custodian maintains insurance with regard to its business on such terms and conditions as it considers appropriate which does not cover the full amount of gold held in custody." When I asked about how much of the gold was insured, the representative proceeded to act as if he didn't know and said they were just the "marketing agent" for GLD. What kind of marketing agent would not know such basic information about a product they are marketing? It seems like they are deliberately hiding information from investors. The people behind GLD do not seem like the most honest types."
A
MQ Marqeta extended its agreement with AFRM Affirm, a Buy Now --- Pay Later category leader, through January 2024, showing the long term commitment its customers are making to build and scale on its platform.
A
Great Results! ASTR delivered on promise to customers and shareholders! Astra is a solid business to invest into with it's current mission and future endeavours.
G
NLSP = MC $28 m---2x BIG Drugs in late stage = CHEAPEST Biotech out there!
C
ASPN Target Raised by Canaccord Genuity Buy » USD 45 » USD 52 Reiterated by HC Wainwright Buy USD 45 » USD 65
CGTX Initiated by Oppenheimer Holdings Outperform » USD 22 Initiated by B. Riley » Buy » USD 27
D
Money is an issues that everyone has for a better and luxurious life, life was hard for me until I started trading Bitcoin and I'm now earning $20,000
B
(ARDS) MCap $52 m--2x BIG Phase 3 Drugs NEAR ready =1000%+ Upside
G
Just SENS it before their FDA approval!!
T
Semiconductor sector is hot! Don't let the intermittent pullbacks sway your positions. Global semiconductor sales are up big. Up 30% yoy and over 3% month to month, according to SIA. Just about all semiconductor and equipment companies are offering strong guidance going forward with no indication of weakness anytime soon. Most claiming they see the shortage lasting through 2022 (MRVL the most recent). This shortage combined with the global expansion taking place AND the evolution of the industry's super "cycle" indicates a strong long term outlook for the industry. Who stands to benefit the most? TSM of course. Along with ASML with their monopoly on advanced EUV that's in great demand by anyone wanting to compete in producing advanced semiconductors. AMAT is the most diversified equipment provider. KLAC is the dominant PDC supplier. MRVL for (5G and Data Center) infrastructure. LRCX for memory. ICHR and UCTT are extreme value plays right now as well that benefit from having the companies listed above as customers. GLTA!
- #1 Canadian LP in Global Medical Cannabis; Total Medical Cannabis Net Revenue Rose 9% Compared to Prior Year; Strong Adjusted Gross Margin before FVA of 68% - Business Transformation Plan on Track; Reiterates Annual Cost Savings of $60 Million to $80 Million, Providing Clear Pathway to Adjusted EBITDA Profitability - Balance Sheet Remains Strong with $440.9 Million of Cash at June 30, 2021; Working Capital Improves by $404.3 Million Compared to Prior Year - Adjusted EBITDA Loss, Excluding Restructuring Costs, Narrows to $13.9 Million, a $17.6 Million Improvement Compared to Prior Year - Total Cannabis Net Revenue, Net of Provisions, of $54.8 Million Compared to $55.2 Million in the Prior Quarter, and $67.5 Million in the Year-Ago Period.
L
VIAC's TV Entertainment and Cable Network are strong cash generators despite the headwinds. PlutoTV and Paramount+ are deeply undervalued!
"CNBC's Bob Pisani also made a highly publicized visit to GLD's gold vault in a segment called Gold Rush: The Mother Lode. GLD's administration organized this visit to show that GLD's gold actually exists. However, the gold bar held up by Mr. Pisani showed a serial number of ZJ6752 which did not show up on the latest bar list during that time. It was later found that this "GLD" bar actually belonged to ETF Securities..."
"Did anyone try calling the GLD hotline at 866 320 4053 in search of numerical details on GLD's insurance? The prospectus vaguely states "The Custodian maintains insurance with regard to its business on such terms and conditions as it considers appropriate which does not cover the full amount of gold held in custody." When I asked about how much of the gold was insured, the representative proceeded to act as if he didn't know and said they were just the "marketing agent" for GLD. What kind of marketing agent would not know such basic information about a product they are marketing? It seems like they are deliberately hiding information from investors. The people behind GLD do not seem like the most honest types."
Target Raised by Canaccord Genuity Buy » USD 45 » USD 52
Reiterated by HC Wainwright Buy USD 45 » USD 65
Target Raised by Benchmark Positive Buy » USD 580 » USD 650
Maintains BTIG Research Buy » USD 610 » USD 700
Initiated by Oppenheimer Holdings Outperform » USD 22
Initiated by B. Riley » Buy » USD 27
Reiterated by Cowen Buy » USD 700
Maintains Oppenheimer Holdings Outperform USD 600 » USD 680
Target Raised by JPMorgan Chase Overweight USD 660 » USD 680
Target Raised by Stifel Nicolaus Buy USD 725 » USD 750
Target Raised by UBS Buy USD 625 » USD 690
Reiterated by Goldman Sachs Buy USD 735 » USD 765
Target Raised by Citigroup Neutral USD 575 » USD 678
Target Raised by Jefferies Buy » USD 750 » USD 760
Maintains Piper Sandler Overweight » USD 600 » USD 670
Maintains Morgan Stanley Equal-Weight USD 34 » USD 37
Maintains Wells Fargo Overweight USD 39 » USD 42
Target Raised by Cowen Outperform USD 184 » USD 223
Maintains Oppenheimer Holdings Outperform USD 205 » USD 225
Maintains Credit Suisse Outperform USD 209 » USD 225
Target Raised by Robert W Baird Outperform » USD 216 » USD 235
- #1 Canadian LP in Global Medical Cannabis; Total Medical Cannabis Net Revenue Rose 9% Compared to Prior Year; Strong Adjusted Gross Margin before FVA of 68%
- Business Transformation Plan on Track; Reiterates Annual Cost Savings of $60 Million to $80 Million, Providing Clear Pathway to Adjusted EBITDA Profitability
- Balance Sheet Remains Strong with $440.9 Million of Cash at June 30, 2021; Working Capital Improves by $404.3 Million Compared to Prior Year
- Adjusted EBITDA Loss, Excluding Restructuring Costs, Narrows to $13.9 Million, a $17.6 Million Improvement Compared to Prior Year
- Total Cannabis Net Revenue, Net of Provisions, of $54.8 Million Compared to $55.2 Million in the Prior Quarter, and $67.5 Million in the Year-Ago Period.
Maintains Wells Fargo Overweight » USD 750 » USD 835
Maintains Canaccord Genuity Buy » USD 685 » USD 830
Maintains Morgan Stanley Equal-Weight USD 252 » USD 262
Target Raised by Credit Suisse Outperform » USD 295 » USD 304